GAM
JAZZ icon

Goldentree Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Goldentree Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.8M Sell
294,435
-181,115
-38% -$39.7M 4.12% 6
2026
Q1 		$89.8M Buy
475,550
+55,209
+13% +$9.65M 5.32% 7
2025
Q4 		$71.3M Sell
420,341
-716,765
-63% -$110M 3.87% 7
2025
Q3 		$150M Buy
+1,137,106
New +$136M 12.36% 2

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Goldentree Asset Management's JAZZ Position: Q2 2026 in Review

Goldentree Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 38% in Q2 2026, selling an estimated $39.7M and leaving 294,435 shares worth $70.8M. The position accounts for 4.12% of the portfolio, ranked #6.

Goldentree Asset Management first reported a position in JAZZ in Q3 2025 and has held it in 4 quarters since. The position peaked at $150M in Q3 2025. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Goldentree Asset Management held 294,435 shares of Jazz Pharmaceuticals worth $70.8M as of Q2 2026.
  • Goldentree Asset Management sold 181,115 Jazz Pharmaceuticals shares in Q2 2026, an estimated $39.7M.
  • Jazz Pharmaceuticals made up 4.12% of Goldentree Asset Management's portfolio in Q2 2026, its #6 holding.
  • Goldentree Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Goldentree Asset Management's Jazz Pharmaceuticals position peaked at $150M in Q3 2025.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Goldentree Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.